Gilead Sciences, Inc.
Close on Nov 2, 2026Market cap $211.20BP/E –Yield 1.86%
Gilead Sciences Total HIV Franchise Product Sales by Year
Total HIV Franchise Product Sales — Rest of World sales ($M) ($M)
Gilead Sciences Total HIV Franchise Product Sales: $1,456M in FY2025, up 7.5% from a year earlier. That is the highest of the 9 years on record here.
Where the FY2025 figure comes from
Source: Form 10-K (filed 2026-02-24) ↗
Reported in Form 10-Q / 10-K Disaggregated Revenue Note & Form 8-K Product Sales Summary.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Total HIV Franchise Product Sales — Rest of World sales ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 1,456 | +7.5% | Form 10-K (filed 2026-02-24) ↗ |
| FY2024 | Dec 31, 2024 | 1,355 | +10.5% | Form 10-K (filed 2026-02-24) ↗ |
| FY2023 | Dec 31, 2023 | 1,226 | +6.1% | Form 10-K (filed 2026-02-24) ↗ |
| FY2022 | Dec 31, 2022 | 1,155 | +3.0% | Form 10-K (filed 2025-02-28) ↗ |
| FY2021 | Dec 31, 2021 | 1,121 | +12.1% | Form 10-K (filed 2024-02-23) ↗ |
| FY2020 | Dec 31, 2020 | 1,000 | +23.3% | Form 10-K (filed 2023-02-22) ↗ |
| FY2019 | Dec 31, 2019 | 811 | +30.2% | Form 10-K (filed 2022-02-23) ↗ |
| FY2018 | Dec 31, 2018 | 623 | -7.2% | Form 10-K (filed 2021-02-25) ↗ |
| FY2017 | Dec 31, 2017 | 671 | – | Form 8-K (exhibit991earningspressrel.htm, filed 2019-02-04) ↗ |
Cite this data
StockData. (2026). Gilead Sciences Total HIV Franchise Product Sales ($M), annual FY2017–FY2025 [Data set]. Compiled from Gilead Sciences SEC filings and investor materials. https://stockdatahq.com/stocks/gild/kpis/hiv-total-row
See every metric in the Gilead Sciences KPI table. Data updated Oct 29, 2026.